A New Combination Therapy Surpasses Semaglutide in Weight Loss Efficacy

Daily Technology

05/03/2026

Recent clinical findings indicate a significant advancement in obesity treatment. A phase II trial combining the GLP-1 drug semaglutide with an experimental antibody, bimagrumab, has demonstrated superior results in weight loss and fat reduction compared to semaglutide administered alone. This development could signal a new era in pharmacological approaches to weight management.

GLP-1 receptor agonists like semaglutide have proven effective in promoting weight loss. However, a portion of the weight lost typically includes lean body mass, which can encompass muscle tissue. While this is a normal outcome of weight reduction, minimizing muscle loss is a key area of research, particularly for populations such as older adults who are more vulnerable to its effects.

The new study introduces bimagrumab, an antibody developed by Eli Lilly that works by inhibiting the activin receptor type-2B. This protein naturally regulates and limits muscle growth. By blocking this receptor, bimagrumab is designed to preserve or increase muscle mass, a mechanism that complements the fat-reducing effects of semaglutide.

The comparative results from the 48-week trial are notable. Participants receiving the combination therapy at the highest dose lost up to 20% of their body weight. In contrast, those on the highest dose of semaglutide alone lost up to 15%, a figure consistent with previous trials. The data further reveals that the combination group achieved a 45.7% decrease in fat mass, substantially higher than the 27.8% reduction in the semaglutide-only group. Crucially, the combination therapy also resulted in significantly less lean body mass loss, with a reduction of only 2.9% from baseline compared to 7.4% for the semaglutide group.

From a safety perspective, the dual-drug regimen was reported as generally safe and tolerable. The side effects observed were consistent with the known profiles of each drug individually, including gastrointestinal symptoms for semaglutide and muscle cramps for bimagrumab.

These findings support the continued development of bimagrumab, either as a standalone treatment or in combination with incretin-based therapies. Eli Lilly is already proceeding with a phase II trial pairing bimagrumab with its own obesity drug, tirzepatide. While traditional methods like resistance training and increased protein intake remain effective for maintaining muscle during weight loss, this combination therapy presents a powerful new pharmacological tool that could optimize outcomes by offering greater fat loss while actively preserving muscle.

2025-10-15

Walmart and OpenAI Forge Partnership to Revolutionize Online Shopping via ChatGPT

Walmart and OpenAI are partnering to allow customers to shop for products directly through ChatGPT, aiming to revolutionize the online shopping experience with AI-powered convenience.